Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22028-22037

  Karlsson, Anna ^a   Brunnström, Hans ^a,b   Lindquist, Kajsa Ericson ^b   Jirström, Karin ^a,b   Jönsson, Mats ^a   Rosengren, Frida ^a   Reuterswärd, Christel ^a   Cirenajwis, Helena ^a   Borg, Åke ^a,c   Jönsson, Per ^c   Planck, Maria ^a,d   Jönsson, Göran ^a,c   Staaf, Johan ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b Lund University   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ALK; Gene fusion; Large cell lung cancer; LCNEC; Mutation

Indexed keywords

NAPSIN A; PROTEIN P40; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ALK GENE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FUSION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE LUNG CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PRIMARY LARGE CELL NEUROENDOCRINE LUNG CANCER; RET GENE; RETROSPECTIVE STUDY; ROS1 GENE; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; VERY ELDERLY; COHORT ANALYSIS; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; SURVIVAL ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEUROENDOCRINE TUMORS; SURVIVAL ANALYSIS;

EID: 84941248870     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4314     Document Type: Article

References (29)

1. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006; 24:70-76.
2. Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 130:166-172.
3. Travis W.D. BE, Muller-Hermelink H.K., Harris C.C. (Eds.). (2004). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. (Lyon: IARC Press).
4. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005; 23:8774-8785.
5. Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol. 2014; 26:511-522.
6. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014; 464:61-68.
7. Travis W.D.BE, Burke A.P., Marx A, Nicholson A.G. (Eds.). (2015). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. (Lyon: IARC Press).
8. CLCGP. A genomics-based classification of human lung tumors. Sci Transl Med. 2013; 5: 209ra13.
9. Staaf J, Isaksson S, Karlsson A, Jonsson M, Johansson L, Jonsson P, Botling J, Micke P, Baldetorp B, Planck M. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. International journal of cancer. 2012; 1:2020-2031.
10. Karlsson A, Jonsson M, Lauss M, Brunnstrom H, Jonsson P, Borg A, Jonsson G, Ringner M, Planck M, Staaf J. Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. Clin Cancer Res. 2014; 20:6127-6140.
11. Iyoda A, Hiroshima K, Moriya Y, Mizobuchi T, Otsuji M, Sekine Y, Shibuya K, Iizasa T, Saitoh Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004; 77:1891-1895; discussion 1895.
12. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, West H, Whitlock S, Somerfield MR. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. J Clin Oncol. 2014.
13. Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, Furuta K, Tsuda H. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013; 66:705-707.
14. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1, 683 patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19:4273-4281.
15. De Pas TM, Giovannini M, Manzotti M, Trifiro G, Toffalorio F, Catania C, Spaggiari L, Labianca R, Barberis M. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011; 29:e819-822.
16. Aroldi F, Bertocchi P, Meriggi F, Abeni C, Ogliosi C, Rota L, Zambelli C, Bna C, Zaniboni A. Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung? A Case Report. Case Rep Oncol. 2014; 7:478-483.
17. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011; 8:381-385.
18. Salomonsson A, Jonsson M, Isaksson S, Karlsson A, Jonsson P, Gaber A, Bendahl PO, Johansson L, Brunnstrom H, Jirstrom K, Borg A, Staaf J, Planck M. Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma. Genes Chromosomes Cancer. 2013; 52:1088-1096.
19. Brunnstrom H, Johansson L, Jirstrom K, Jonsson M, Jonsson P, Planck M. Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol. 2013; 140:37-46.
20. Karlsson A, Ringner M, Lauss M, Botling J, Micke P, Planck M, Staaf J. Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history. Clin Cancer Res. 2014; 20:4912-4924.
21. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America. 1971; 68:820-823.
22. Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol. 2014; 67:772-776.
23. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. The Journal of pathology. 2004; 204:101-109.
24. Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, Rossi G, Morelli L, Cucino A, Silvestri M, Tirone G, Pelosi G, Graziano P, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011; 136:773-782.
25. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009; 22:709-717.
26. Monica V, Scagliotti GV, Ceppi P, Righi L, Cambieri A, Lo Iacono M, Saviozzi S, Volante M, Novello S, Papotti M. Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res. 2009; 15:7547-7552.
27. Pardo J, Martinez-Penuela AM, Sola JJ, Panizo A, Gurpide A, Martinez-Penuela JM, Lozano MD. Large cell carcinoma of the lung: an endangered species? Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 2009; 17:383-392.
28. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England journal of medicine. 2014; 371:1963-1971.
29. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3:630-635.